Joel S. Marcus

Joel S. Marcus, listed as chief executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Alexandria Real Estate Equities, Inc., Intra-Cellular Therapies, Inc. and Applied Therapeutics Inc. Between 31 December 2015 and 13 October 2026, the trades on record add up to 50 filings.

Market trades split into 4 purchases (€1.5M) and 13 sales (€10.9M). On balance, insiders were net sellers of €9.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 18 share grants and 9 option exercises. Since January 2026: 4 purchases and no sales on the market.

The median purchase comes to €282k. Relative to company size, the median is 0.0027% of market cap (3 purchases with a known value). Across 4 purchases, this insider has always bought alone, with no colleague buying within 30 days.

Most recently, on 13 October 2026, the filings show a transaction in TRex Bio, Inc. The clock since the last published purchase (15 September 2026) now reads 33 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.